Neurology

In honor of World Brain Day, observed annually on July 22 by patient and clinician communities, CGTLive is taking a closer look at this ongoing study.

Paul Y. Song, MD, the chairman and chief executive officer of NKGen, discussed the potential of SNK01, the company’s autologous natural killer cell therapy, in treating PD.

Passage Bio received the feedback on a proposal to amend the upliFT-D protocol in the context of a Type C meeting process with the FDA.

Review top news and interview highlights from the week ending July 19, 2024.

Longeveron will present updated data from the phase 2a CLEAR MIND study at AAIC 2024 at the end of July.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The FDA announced its START Pilot Program in October 2023 with a similar goal.

Patient enrollment is anticipated to begin in the first quarter of 2025.

Data from the high-dose cohort of a phase 1/2 clinical trial in South Korea will be shared in Fall 2024.

Despite the improvements, Lexeo was unable to discern a benefit on cardiovascular fitness and Peak VO2 from LX2006 with current measurements.

Ignacio Mata, PhD, an associate professor of neurology at the Cleveland Clinic Lerner Institute, pointed out that genetic forms of PD are relatively well-understood compared to other types.

Review top news and interview highlights from the week ending July 12, 2024.

The BCT-006-US trial is set to begin dosing this year.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Treated patients had a –0.2 mean change in cUHDRS compared with a –1.0 change in external control data.

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

Deborah Phippard, PhD, the chief scientific officer of Precision for Medicine, discussed unique difficulties of designing clinical trials for PD gene therapy candidates.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

Review top news and interview highlights from the week ending July 5, 2024.

The therapy, rAAV-Olig001-ASPA, has shown positive clinical benefits in several interim updates from an ongoing, first-in-human phase 1/2 clinical trial (NCT04833907).

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The company has reported data in NMOSD, myasthenia gravis, and necrotizing myopathy over the last several months.

Cartesian also announced that the first patient has been dosed in a separate clinical trial evaluating the CAR-T therapy in systematic lupus erythematosus.

The placebo-controlled multidose portion of the SELECT-HD trial included 23 patients with Huntington Disease in total.

Various improvements were seen in 2 adult patients and 2 pediatric patients treated in separate clinical trials.

Review top news and interview highlights from the week ending June 28, 2024.

The cofounder and chief executive officer of Kate Therapeutics discussed research that awarded him an Outstanding New Investigator at the ASGCT 2024 meeting.

The company has begun enrolling participants in a new cohort for younger patients in the phase 1/2 AFFINITY DUCHENNE clinical trial.

Three participants with ATTR amyloidosis have received follow-on doses of NTLA-2001 with no serious complications for up to 3 years of follow-up.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.